GLAXOSMITHKLINE PLC Form 6-K April 19, 2017
FORM 6-K
SECURITIES AND EXCHANGE COMMISSION
Washington D.C. 20549
Report of Foreign Issuer
Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934
For period ending 19 April 2017
GlaxoSmithKline plc
(Name of registrant)
980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address of principal executive offices)
Indicate by check mark whether the registrant files or
will file annual reports under cover Form 20-F or Form 40-F
Form 20-F x Form 40-F

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the

Securities Exchange Act of 1934.

Yes No x

GlaxoSmithKline plc (the 'Company')

Transaction notification

1. Details of PDMR/person closely associated with them ('PCA')

a) Name Ms E Walmsley

b) Position/status

Chief Executive Officer

Initial notification/ c) Initial notification

amendment

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a) Name GlaxoSmithKline plc b) LEI 5493000HZTVUYLO1D793

Details of the transaction(s): section to be repeated for (i) each type of

3. instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

> Ordinary shares of 25 pence each ('Ordinary Shares')

a) Description of the financial instrument

ISIN: GB0009252882

Acquisition of Ordinary Shares following the

b) Nature of the transaction re-investment of dividends

paid to shareholders on 13

April 2017.

Price(s) Volume(s) c) Price(s) and volume(s) £16.4042 448.783

n/a (single transaction) Aggregated information

d)

Aggregated volume Price

e) Date of the transaction 2017-04-18

Place of the transaction London Stock Exchange f)

(XLON)

Shares following the re-investment of dividends paid to shareholders on 13

1. Details of PDMR/person closely associated with them ('PCA') a) Name Mr R G Connor President, Global b) Position/status Manufacturing & Supply Initial notification/ Initial notification c) amendment Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor a) Name GlaxoSmithKline plc b) LEI 5493000HZTVUYLO1D793 Details of the transaction(s): section to be repeated for (i) each type of 3. instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted Ordinary shares of 25 pence each ('Ordinary Shares') Description of the financial instrument ISIN: GB0009252882 Acquisition of Ordinary Shares following the b) Nature of the transaction re-investment of dividends paid to shareholders on 13 April 2017. Price(s) Volume(s) c) Price(s) and volume(s) £16.4042 403.744 Aggregated information n/a (single transaction) d) Aggregated volume Price e) Date of the transaction 2017-04-18 Place of the transaction London Stock Exchange f) (XLON) 1. Details of PDMR/person closely associated with them ('PCA') a) Name Mr L Debruyne b) Position/status President, Global Vaccines Initial notification/ Initial notification amendment Details of the issuer, emission allowance market participant, auction 2. platform, auctioneer or auction monitor a) Name GlaxoSmithKline plc 5493000HZTVUYLO1D793 b) LEI Details of the transaction(s): section to be repeated for (i) each type of 3. instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted Ordinary shares of 25 pence each ('Ordinary Shares') Description of the financial instrument ISIN: GB0009252882 b) Nature of the transaction **Acquisition of Ordinary**

	Edgar Filing: GLAXOSMITHKLINE PLC			
c)	Price(s) and volume(s)	April 2017. Price(s) £16.4042	Volume(s) 1,079.517	
d)	Aggregated information	n/a (single tr	ansaction)	
e) f)	Aggregated volume Price Date of the transaction Place of the transaction	2017-04-18 London Stock Exchange (XLON)		
1. a) b) c)	Details of PDMR/person closely associa Name Position/status Initial notification/ amendment	nted with them ('PCA') Mr S Dingemans Chief Financial Officer Initial notification		
2.	Details of the issuer, emission allowance platform, auctioneer or auction monitor	e market partio	cipant, auction	
a) b)	Name LEI	GlaxoSmithI 5493000HZ	Kline plc ΓVUYLO1D793	
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted Ordinary shares of 25 pence			
a)	Description of the financial instrument	each ('Ordina	_	
b)	Nature of the transaction	paid to share April 2017.	of Ordinary wing the at of dividends holders on 13	
c)	Price(s) and volume(s)	Price(s) £16.4042	Volume(s) 871.935	
d)	Aggregated information Aggregated volume Price	n/a (single transaction)		
e)	Date of the transaction Place of the transaction	2017-04-18 London Stock Exchange (XLON)		
f)	i face of the transaction			
1. a)	Details of PDMR/person closely associa Name	Mr S A Hussain		
b)	Position/status	President, Global Pharmaceuticals		
c)	Initial notification/ amendment	Initial notification		
2.	Details of the issuer, emission allowance	e market partic	cipant, auction	

platform, auctioneer or auction monitor

GlaxoSmithKline plc

5493000HZTVUYLO1D793

a) Name

b) LEI 3.

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

> Ordinary shares of 25 pence each ('Ordinary Shares')

Description of the financial instrument

ISIN: GB0009252882 **Acquisition of Ordinary** Shares following the

b) Nature of the transaction re-investment of dividends

paid to shareholders on 13

April 2017.

Price(s) Volume(s) c) Price(s) and volume(s) £16.4042 1,375.318

Aggregated information n/a (single transaction)

d)

Aggregated volume Price

Date of the transaction 2017-04-18

Place of the transaction London Stock Exchange

(XLON)

1. Details of PDMR/person closely associated with them ('PCA')

a) Name Mr D S Redfern b) Position/status Chief Strategy Officer

Initial notification/ c)

Initial notification amendment

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a) Name GlaxoSmithKline plc

b) LEI 5493000HZTVUYLO1D793

Details of the transaction(s): section to be repeated for (i) each type of

instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

Ordinary shares of 25 pence

Description of the financial instrument

each ('Ordinary Shares') ISIN: GB0009252882

Acquisition of Ordinary Shares following the re-investment of dividends

b) Nature of the transaction paid to shareholders on 13

April 2017.

Price(s) Volume(s) c) Price(s) and volume(s) 1,471.854 £16.4042

Aggregated information n/a (single transaction)

d) Aggregated volume Price

Date of the transaction 2017-04-18

Place of the transaction London Stock Exchange

f) (XLON)

Shares following the re-investment of dividends paid to shareholders on 13

1. Details of PDMR/person closely associated with them ('PCA') a) Name Ms C Thomas b) Position/status SVP, HR Initial notification/ Initial notification amendment Details of the issuer, emission allowance market participant, auction 2. platform, auctioneer or auction monitor a) Name GlaxoSmithKline plc b) LEI 5493000HZTVUYLO1D793 Details of the transaction(s): section to be repeated for (i) each type of 3. instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted Ordinary shares of 25 pence each ('Ordinary Shares') Description of the financial instrument ISIN: GB0009252882 Acquisition of Ordinary Shares following the Nature of the transaction re-investment of dividends paid to shareholders on 13 April 2017. Price(s) Volume(s) c) Price(s) and volume(s) £16.4042 478.351 Aggregated information n/a (single transaction) d) Aggregated volume Price e) Date of the transaction 2017-04-18 Place of the transaction London Stock Exchange f) (XLON) 1. Details of PDMR/person closely associated with them ('PCA') a) Name Mr P C Thomson President, Global Affairs b) Position/status Initial notification/ Initial notification amendment Details of the issuer, emission allowance market participant, auction 2. platform, auctioneer or auction monitor a) Name GlaxoSmithKline plc b) LEI 5493000HZTVUYLO1D793 Details of the transaction(s): section to be repeated for (i) each type of 3. instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted Ordinary shares of 25 pence each ('Ordinary Shares') Description of the financial instrument ISIN: GB0009252882 b) Nature of the transaction **Acquisition of Ordinary**

.C - Form 6-K

	Edgar Filing: GLAXOSMITHKLINE PLC			
c)	Price(s) and volume(s) Aggregated information	April 2017. Price(s) £16.4042 n/a (single tra	Volume(s) 690.515 ansaction)	
d)e)f)	Aggregated volume Price Date of the transaction Place of the transaction	2017-04-18 London Stock Exchange (XLON)		
 a) b) c) 	Details of PDMR/person closely associa Name Position/status Initial notification/ amendment Details of the issuer, emission allowance	Dr P J T Vallance President, R&D Initial notification		
a)b)3.	platform, auctioneer or auction monitor Name LEI Details of the transaction(s): section to b instrument; (ii) each type of transaction; place where transaction(s) has been cond	(iii) each date; and (iv) each		
a)	Description of the financial instrument		res of 25 pence ary Shares')	
b)	Nature of the transaction	ISIN: GB0009252882 Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 13 April 2017. Price(s) Volume(s)		
c)	Price(s) and volume(s)	£16.4042	2,767.208	
d)	Aggregated information Aggregated volume Price	n/a (single transaction)		
e) f)	Date of the transaction Place of the transaction	2017-04-18 London Stock Exchange (XLON)		
1. a)	Details of PDMR/person closely associa Name	sociated with them ('PCA') Mrs K Thomson		
b)	Position/status	PCA of Mr P C Thomson (President, Global Affairs)		
c)	Initial notification/ amendment	Initial notification		
2.	Details of the issuer, emission allowance		ipant, auction	

platform, auctioneer or auction monitor

GlaxoSmithKline plc

5493000HZTVUYLO1D793

a) Name

b) LEI

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

Ordinary shares of 25 pence each ('Ordinary Shares')

a) Description of the financial instrument

ISIN: GB0009252882 Acquisition of Ordinary Shares following the

b) Nature of the transaction

re-investment of dividends paid to shareholders on 13

April 2017.

c) Price(s) and volume(s)

Price(s) Volume(s) £16.4042 130.423

Aggregated information

n/a (single transaction)

d)

Aggregated volume Price

e) Date of the transaction 2017-04-18

Place of the transaction

London Stock Exchange

(XLON)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GlaxoSmithKline plc (Registrant)

Date: April 19, 2017

By: VICTORIA WHYTE

Victoria Whyte Authorised Signatory for and on behalf of GlaxoSmithKline plc